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Abstract  
Pulmonary disease remains a primary source of morbidity and mortality in persons living with 
HIV (PLWH), although the advent of potent combination antiretroviral therapy (cART) has 
resulted in a shift from predominantly infectious to noninfectious pulmonary complications.  
PLWH are at high risk for chronic obstructive pulmonary disease, pulmonary hypertension, and 
lung cancer even in the era of cART.  The underlying mechanisms of this are incompletely 
understood, but recent research in both human and animal models suggest that oxidative 
stress, expression of matrix metalloproteinases, and genetic instability may result in lung 
damage which predisposes PLWH to these conditions.  Some of the factors which drive these 
processes include tobacco and other substance use, direct HIV infection and expression of 
specific HIV proteins, inflammation, and shifts in the microbiome towards pathogenic and 
opportunistic organisms.  Further studies are needed to understand the relative importance of 
these factors to the development of lung disease in PLWH.   
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Abbreviations: 
HIV: human immunodeficiency virus 
AIDS: acquired immunodeficiency syndrome 
cART: combination antiretroviral therapy 
COPD: chronic obstructive pulmonary disease 
HIV-PAH: HIV associated pulmonary arterial hypertension 
IVDU: intravenous drug use 
PFT: pulmonary function test 
DLCO: diffusing capacity of the lung for carbon monoxide 
BAL: bronchoalveolar lavage 
PD-1: programmed death 1 
EC: endothelial cells 
MACS: multicenter AIDS cohort 
SIV: simian immunodeficiency virus 
AM: alveolar macrophages 
INHALD: Investigating HIV associated mechanisms of lung disease consortium 
PBMC: peripheral blood mononuclear cells 
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INTRODUCTION 
Pulmonary complications remain a significant source of morbidity and mortality in 
patients infected with human immunodeficiency virus (HIV).  Prior to the advent of combination 
antiretroviral therapy (cART), pulmonary infections, especially Pneumocystis jiroveci, 
tuberculosis and community acquired pneumonia, were among the leading causes of death 
1
.  
With the advent of cART, non-infectious pulmonary complications have become more prevalent 
in persons living with HIV (PLWH), including chronic obstructive pulmonary disease (COPD), HIV 
related pulmonary artery hypertension (HIV-PAH) and lung cancer 
2;3; 4
.  The prevalence of 
COPD in PLWH in the modern cART era varies by study and by definition, but by spirometry 7-
9% of PLWH have clinical obstruction, while one third have respiratory symptoms 
5;6
.  The 
prevalence of PAH is 2500 times higher than in the general population, with 0.5% of PLWH 
estimated to have HIV-PAH, despite effective cART 
7
.  The incidence of lung cancer is 2.7 times 
higher in PLWH than in the general population 
8;9
.  The mechanisms underlying the increased 
rates of noninfectious lung disease are multifactorial.  High rates of tobacco use and 
intravenous drug use (IVDU) likely contribute, in addition to chronic lung inflammation and 
subsequent oxidative stress and tissue damage.  In this review, we discuss what is currently 
known about the pathogenesis of COPD, PAH, and lung cancer in PLWH, describe other 
potential relevant mechanisms of lung damage which may contribute to these diseases (Figure 
1), and outline priorities for better understanding the underlying mechanisms in the current 
cART era.   
HIV AND COPD 
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COPD is highly prevalent among cigarette smokers, and incidence increases with age 
10
.  
As PLWH are living longer, high smoking rates contribute to increasing incidence of COPD 
3
.  
Rates of hospitalization for obstructive lung disease have increased for PLWH in the cART era, 
and are expected to increase further as the population ages 
2
.  Several studies have 
demonstrated that PLWH have higher rates of dyspnea and alterations in pulmonary functions 
tests (PFT), particularly low diffusing capacity of the lung for carbon monoxide (DLCO), as well 
as imaging findings of emphysema
4;5;6
.  PLWH also appear to have more respiratory symptoms, 
including dyspnea and cough, than smokers with similar disease burden by PFT criteria 
6
.   
Inflammation plays an important role in the pathogenesis of COPD in PLWH.  Reduced 
frequencies and absolute numbers of CD4+ T cells are seen in bronchoalveolar lavage (BAL) of 
PLWH with COPD 
12
.  These CD4+ T cells, but not CD8+ T cells, demonstrate impaired lung 
mucosal immunity to HIV, and express high levels of programmed cell death 1 (PD-1), a marker 
of immune activation and exhaustion.  They also express high levels of the Fas death receptor, 
CD95, and demonstrate increased Fas-dependent activation induced cell death 
12
.  All of these 
findings result in progressive loss of CD4+ T cells in the BAL, leading to a profound imbalance in 
CD4:CD8 ratio and persistent CD8+ T cell alveolitis in HIV-associated COPD.  This inflammation 
leads to the expression of inflammatory cytokines and release of matrix metalloproteinases 
associated with COPD 
13;14
. 
HIV-PAH 
 The association between HIV infection and pulmonary hypertension was recognized 
early on in the AIDS epidemic 
15
.  Although cART may have decreased the incidence of HIV-PAH 
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and has been shown to partially reverse pulmonary hypertension in a small number of PLWH 
7
, 
PAH remains a significant clinical complication in PLWH, particularly as life expectancy 
increases.  Symptoms and signs usually present late, and half of patients with HIV-PAH die 
during a median follow-up period of 8 months 
16
, although a more recent study demonstrated 
that three year survival is 72% in patients treated with both cART and specific PAH therapy 
17
.  
Specific therapy for PAH appears to improve hemodynamic parameters more than cART, as 
cART has minimal effect even if it is instituted early in disease 
18
.  Approximately two-thirds of 
deaths are attributed to pulmonary hypertension rather than complications of immune 
deficiency 
16;15
.  CD4+ T cell count is the only independent predictor of survival, and patients 
with HIV-PAH have poorer survival rates when compared to uninfected patients with PAH 
15;16
.   
Direct HIV infection, substance abuse and chronic inflammation are particularly 
important in the development of HIV-PAH 
19
.  Chronic exposure to HIV viral proteins in the lung 
(e.g. Nef, Tat, gp120), as well as HIV-induced immune dysregulation, contribute to pulmonary 
vascular disease, particularly through an impact on pulmonary endothelial cells (EC).  HIV Nef 
protein co-localizes with EC in PAH- like plexiform lesions in animal models 
20
. Substance abuse 
also plays a significant role.  In animal models, cocaine increases proliferation of pulmonary 
vascular endothelial cells and morphine contributes to vascular disease and oxidant stress 
21;22
.   
HIV AND LUNG CANCER 
Lung cancer is the primary cause of cancer related death among PLWH 
8
.  Low CD4+ T cell 
counts and prior pneumonia are associated with lung cancer risk 
23;24
.  Cigarette smoke, HIV 
infection and chronic inflammation can increase oxidative stress, leading to oxidative DNA 
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lesions and DNA double strand breaks.  Incorporation of the HIV genome into infected cells is 
dependent on host cell DNA repair proteins, and HIV-induced alterations in DNA repair proteins 
have been implicated in augmenting genomic integration and replication in host cells 
25
.  HIV 
Tat protein in vitro can induce expression of pro-oncogenes (c-myc, c-fos, c-jun) and 
downregulate the p53 tumor suppressor gene 
26
.  Although cART can have genotoxic effects, no 
association has been found between cART and lung cancer risk, and early cART is associated 
with decreased risk 
27
.   
COMMON MECHANISMS OF LUNG DISEASE IN PLWH 
The cause of higher rates of noninfectious lung complications in PLWH is multifactorial.  
PLWH demonstrate evidence of chronic lung inflammation from a variety of causes, including 
direct effects of HIV, cART, illicit drug use, immunodeficiency, opportunistic infections, and 
alterations in the lung microbiome.  The potential mechanisms by which these factors 
contribute both specifically and generally to HIV-PAH, COPD and lung cancer are outlined in 
Figure 1. 
SMOKING AND HIV 
The prevalence of smoking in PLWH ranges from similar to twice that of the general 
population depending on the comparison group.  The largest study demonstrated that 42% of 
PLWH are current smokers, compared to 21% of the general population 
28
.  In contrast, when 
the comparison group consists of uninfected subjects with a high smoking prevalence, such as 
the Veterans’ Aging Cohort Study (VACS) or Multicenter AIDS Cohort Study (MACS) cohort 
which matches patients with similar risk profiles, smoking rates are more similar in the two 
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groups, although PLWH still have higher rates 
29;30
.   Compared to non-smokers,  PLWH who 
smoke have higher levels  of inflammatory markers, including soluble CD14 and expression of 
HLA-DR on both CD8+ and CD4+ T cells 
31;32
.  Cigarette smoking has been linked to increased 
rates of mortality due to cardiovascular disease, COPD, pneumonia, and lung cancer 
29
.  If HIV is 
treated, modeling studies suggest that PLWH who smoke lose over six years of life expectancy, 
more than that lost to HIV infection 
33
. 
PLWH are less likely to quit than the general population (32% vs 52%) 
28
.  Multiple 
factors are associated with continued smoking in PLWH, including higher rates of other 
substance abuse, psychiatric disorders, low socioeconomic status and poor access to care 
34
.  
Perhaps because of multiple competing interests and limited time to address medical issues, 
counseling on smoking cessation happens less frequently for PLWH than the general population 
35
.   
 Despite clear evidence that cigarette smoking contributes to significant disease in 
PLWH, most studies of smoking related illness are poorly controlled for the impact of 
cumulative exposure to cigarette smoke, and control only for smoking status, i.e. current, past 
or nonsmoking status.  A recent study clearly demonstrated that both cumulative pack-year 
smoking history and time since smoking cessation are more strongly associated with lung and 
heart disease than smoking status 
36
, suggesting that a true understanding of the role of 
cigarette smoke as a pathogenic factor in HIV-associated lung disease will require better 
collection of data on total tobacco exposure. 
HIV INFECTION 
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 HIV pathology in the lung is driven by infection of CD4+ T cells and alveolar 
macrophages, which play an important role in the development of pulmonary disease 
37;38
.  
Animal models demonstrate that the lungs and intestines harbor the highest levels of simian 
immunodeficiency virus (SIV) among non-lymphoid tissues 
39
, and early in infection, CD4+ T 
cells are rapidly depleted from mucosal sites 
37;40
.  Recent data suggests that lung epithelium 
can also be directly infected by HIV, especially CXCR4-tropic strains associated with advanced 
disease.   HIV infection results in integration of the viral genetic material into the cellular genome.   This 
integration may change gene expression and immune response 
41
.   Expression of viral proteins, such 
as Tat, increases inflammation and oxidative stress in animal models 
42
.  HIV infection alters the 
function of airway epithelial cells by impairing cell-cell adhesion and increasing the expression 
of inflammatory mediators 
43
.   Thus HIV infection contributes to lung disease by both direct 
effects of infection and through modulation of systemic inflammation and immunodeficiency. 
COMBINATION ANTIRETROVIRAL THERAPY (cART) 
 Treatment of HIV-1 infection with cART has generally been associated with improved 
outcomes 
29
, especially in reduction of infectious pulmonary complications.  Its influence on 
non-infectious pulmonary complications has been more controversial.  Protease inhibitor use has 
been linked to an increased incidence of malignancy, although not lung cancer specifically 
27
.  Older 
antiretrovirals may have had genotoxic effects which contribute to this increased risk.  Although one 
study demonstrated that cART increased the risk of COPD 
44
, the pulmonary substudy embedded in the 
large Strategic Timing of Antiretroviral Therapy (START) trial demonstrated that the timing of ART had 
no effect on COPD progression 
45
, and  poor HIV control in a predominant smoking population is 
associated with the development of HIV-associated COPD and accelerated annual lung decline 
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46
.  Antiretroviral use  improves hemodynamics and survival in HIV-PAH, although not as dramatically as 
PAH therapy 
18;47
.   
INFLAMMATION IN THE LUNG 
From early in the epidemic, it was noted that HIV infection is associated with a CD8+ T 
cell alveolitis, that occurs in both asymptomatic patients and those with respiratory symptoms 
and HIV disease progression  
48
.  Many of these cytotoxic T cells are directed against HIV-
infected cells or other opportunistic pathogens (i.e. cytomegalovirus, Pneumocystis) 
49;50
.  Lung 
CD8+ T cells appear to be dysfunctional, expressing high levels of the exhaustion marker, PD-1, 
in the absence of antiviral therapy 
49
.  Lymphocytes expressing exhaustion markers such as PD-1 
and CD57 are thought to be terminally differentiated senescent cells.  However, CD8+ T cells 
maintain the capacity to secrete a pro-inflammatory effector cytokines in response to HIV 
antigens under conditions of poor viral control as well as following viral suppression 
12;49;51
.  
Thus, the presence of terminally differentiated effector lymphocytes in the lung contributes to 
local inflammation in response to HIV itself, as well as other pathogens. HIV infection can cause 
lung inflammation in other ways as well.  For example, alveolar macrophages (AM) are infected 
by HIV, even in healthy, nonsmoking PLWH, and infected cells have impaired phagocytic 
function as well as abnormal oxidative burst and cytokine secretion 
52;53
.  Untreated PLWH who 
smoke showed significant lung CD4+ T cell dysfunction and depletion, along with high 
susceptibility to apoptosis, which improved following cART 
51
.   
Thus, HIV-associated lung disease in PLWH likely is driven by multiple inflammatory 
mechanisms: 1) HIV replication in lung CD4+ T cells and AM, 2) CD8+ T cell alveolitis and an 
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imbalance of the physiologic lung CD4:CD8 ratio, 3) progressive CD4+ T cell 
depletion/dysfunction, 4) dysregulation of alveolar macrophages, and 5) impaired immune 
function to other pathogens, which predisposes to infection and parenchymal damage.  
Together with tobacco exposure, this combination of cellular activation and immune 
dysfunction contributes to the pathogenesis of lung disease. 
HIV ASSOCIATED PULMONARY INFECTIONS AND THE MICROBIOME 
Recent studies have revolutionized our understanding of the role the microbiome plays 
in health and disease 
54
.  Although the microbial community is smaller in the lung than in the 
gut, it is clear that it is diverse and modulated by disease 
55;56
.  Pulmonary flora is modulated by 
inhaled corticosteroids or bronchodilator use 
56
, while smoking has minimal effects on the lung 
microbiome 
56;57
.  In general, most inflammatory disease states, such as COPD, are associated 
with a decline in microbiome diversity, and increased abundance of inflammatory 
Proteobacteria species, such as Pseudomonas, Moraxella, and Haemophilus influenzae 
55;56
.   
Changes in the bacterial microbiome of the lung have been described in HIV infection, 
and may account for increased pathology at both these sites particularly with advanced 
immunodeficiency.  The first study of the lung microbiome in HIV infection demonstrated an 
increased prevalence of Tropheryma whipplei in untreated subjects, although a broader 
comprehensive analysis of upper and lower bacterial microbiomes using 16S rRNA methods did 
not demonstrate a significant difference in bacterial communities between healthy PLWH and 
uninfected individuals 
58;59
.  In contrast, PLWH with low CD4+ T cell counts have fewer numbers 
of species (decreased alpha diversity), although more unique species are present (increased 
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beta diversity) 
59;60
.  The HIV lung microbiome contains increased amounts of Veillonella and 
Prevotella, bacteria previously shown to be associated with inflammation 
61
.  An increase in 
detection of Pneumocystis jiroveci is associated with both HIV infection and COPD 
62
.   
HIV pathogenesis is characterized by gastrointestinal CD4+ T cell depletion and a 
compromised mucosal barrier, leading to microbial translocation, endotoxemia and systemic 
immune activation 
40
.   Shifts in the gut microbiome have also been seen in PLWH 
63;11
, although 
the extent to which this is due to HIV infection versus other factors, such as sexual preference, 
is still unclear
64
.  In addition to systemic immune activation, which appears to be related to 
gastrointestinal pathology, changes in the gut microbiome may have a particular influence on 
pulmonary disease.  Several epidemiologic studies, as well as studies in murine models, have 
demonstrated a correlation between susceptibility to pulmonary infections, allergic airway 
disease and an altered fecal microbiome 
65
.  There is an epidemiologic correlation between 
COPD and inflammatory bowel disease 
66
, which may be smoking related, but may also be due 
to shifts in the microbiome, inflammation or modulation of matrix metalloproteinases 
67
.   
OXIDATIVE STRESS 
The lung is at particular risk of damage due to excessive oxidative stress, because it is 
directly exposed to oxygen, inhaled pollutants, and microbes that produce pro-oxidant reactive 
oxygen and nitrogen species.  Higher levels of markers of oxidative stress and lower levels of 
antioxidant glutathione are found in smokers, as well as patients with COPD and/or HIV 
68
.  
Oxidative stress is worsened during acute exacerbations of COPD 
69
.  HIV infection is associated 
with high rates of oxidative stress 
68
, which may be due to the direct effects of the viral 
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proteins, gp120 and tat, on lung epithelium 
42
.  Alcohol and tobacco use by HIV-infected 
patients contribute to oxidative stress, potentially through the involvement of antioxidant 
pathways and the cytochrome P450 system 
70
.    
MATRIX METALLOPROTEINASES (MMP) 
MMPs are a large family of zinc-dependent endopeptidases that can cleave the majority 
of structural components of the extracellular matrix, including elastin.  Studies have identified 
increased proteolytic activity in PLWH who smoke and have emphysema 
13
, and examination of 
their BAL confirmed elevated expression of MMP mRNA in alveolar macrophages, and MMP 
protein and activity in supernatant. Recent studies have demonstrated that high levels of 
inflammatory cytokines, such as IL-23, are seen in the BAL of these patients.  Infection of AM 
results in expression of IL-23, which can lead to upregulation of MMP 9 in AM in an 
AM/lymphocyte co-culture model 14.   Studies of human macrophages have consistently located 
MMP-12 and MMP-9 in emphysematous lung 
71
. Murine models have demonstrated that 
macrophage overexpression of MMP-9 or MMP-1 can spontaneously induce emphysema, while 
MMP-12 knockdown is protective from cigarette smoke-induced emphysema 
72
.  MMP 
expression is additionally upregulated and has been demonstrated to play an important role in 
the development of PAH in animal models 
73
.  It is notable that MMP-12 is quite responsive to 
smoking cessation and if this protease has an exaggerated role in HIV-mediated lung disease, 
smoking cessation may result in an even more significant impact in this cohort 
74
.   
  
ADDRESSING MOLECULAR MECHANISMS OF LUNG DISEASE IN HIV 
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We currently are at a critical point in investigating lung disease in PLWH.  The continued 
development of less toxic cART has resulted in more persistent and robust recovery of immune 
function.  Nonetheless, a recent study highlighted both a significant under-prescription of cART 
and ineffective viral suppression in PLWH 
75
.  The institution of more generalized screening of 
individuals at risk for HIV has resulted in fewer opportunistic infections and specialized care 
earlier in disease.  Although issues like smoking and IVDU are difficult to treat, the 
epidemiology from several large cohorts has made the potential size of our future problem 
quite clear.  At this time a major knowledge gap remains whether lung disease is occurring at a 
very rapid rate prior to treatment or if there is continued accelerated decline with disease even 
on cART.  In addition, cohorts comprised of subjects over age 40 are needed to longitudinally 
assess lung T cell subsets, antigen-specific immunity including HIV-specific responses, 
macrophage activation and Pneumocystis colonization to determine which of these predict 
progression of lung disease.  Further, there is a need to study patients who have not had 
significant immune suppression and opportunistic infections to evaluate whether they are at 
high risk of lung disease in the absence of advanced immunodeficiency.  
Another unmet need is the execution of well-designed mechanistic studies on the 
pathogenesis of lung disease.  To understand the mechanisms of HIV-associated inflammation, 
we must define the relative importance of a variety of potential causes of inflammation: HIV 
itself; tobacco, alcohol and illicit drug use; opportunistic infections; shifts in the microbiome to 
organisms capable of causing chronic inflammation (bacteria such as Prevotella, persistent 
latent virus infection, persistent fungi such as Pneumocystis), current antiretroviral drugs, or 
other as yet unidentified mechanisms.  Understanding these factors may be critical to our 
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understanding of other inflammatory disorders in PLWH, and may allow us to develop 
therapeutic interventions to alter the progression of disease.   
The INvestigating HIV-Associated Lung Disease (INHALD) consortium 
(http://statepiaps.jhsph.edu/lamdacc/inhald/index.html) is a collaborative effort designed to 
evaluate and understand the mechanisms of lung disease in PLWH.  The INHALD cohort will 
provide invaluable data to assist in our understanding of lung disease in patients during the 
modern era of cART, and will generate information about specific downstream mechanisms.  .  
Sites are conducting assessments including pulmonary function testing, imaging, and 
echocardiography.  Biologic samples, including blood, peripheral blood mononuclear cells 
(PBMC) and BAL are being collected and banked.  Sites are collaborating on projects to evaluate 
the microbiome (with a particular focus on virome and shotgun metagenomics), inflammation, 
and oxidative stress, and welcome outside collaborations.  As the HIV-infected population ages, 
lung disease is likely to become an increasingly common comorbidity given high rates of 
smoking in this population.  Appropriate management will require an understanding of 
modifiable mechanisms of disease to define best practices.   
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